Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).
John Martignetti
Research Funding - Karyopharm Therapeutics
Albiruni R.A. Razak
Research Funding - Karyopharm Therapeutics
Ying Chen
Research Funding - Karyopharm Therapeutics
Nashat Y. Gabrail
No relevant relationships to disclose
John F. Gerecitano
No relevant relationships to disclose
Catalina Camacho
Research Funding - Karyopharm Therapeutics
Elena Pereira
Research Funding - Karyopharm Therapeutics
Peter Remsen Dottino
Research Funding - Karyopharm Therapeutics
Sharon Shacham
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Dilara McCauley
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Tami Rashal
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Jean-Richard Saint-Martin
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Eran Shacham
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Darcy Vincett
No relevant relationships to disclose
Michael Kauffman
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Mansoor Raza Mirza
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Morten Sorensen
Research Funding - Karyopharm Therapeutics